Abstract
Vitiligo is acommon skin disease leading to depigmentation that is associated with progressive destruction of melanocytes. The main subtype, nonsegmental vitiligo (NSV), is considered achronic autoimmune disease leading to activation of melanocyte-specific CD8+ lymphocytes and development of acutaneous immune memory. Vitiligo can result in significant impairment of quality of life and is associated with anumber of comorbidities. Despite the existence of national guidelines and international treatment recommendations, there is astrong need for improved health care for patients with vitiligo. The options in the treatment algorithm for vitiligo are similar and consisted until recently of only topical and systemic corticosteroids, topical calcineurin inhibitors, phototherapy, and surgical interventions. New insights into the pathobiological role of the interferon signature in vitiligo have most recently contributed to the approval of the first vitiligo-specific therapy with the topical Janus kinase1/2 inhibitor ruxolitinib for patients with NSV.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call